ubmslatePT-logo-ubm

PT Mobile Logo

Search form

Topics:

What’s New in Bipolar Depression?

What’s New in Bipolar Depression?

©Namning/Shutterstock

Therapeutic imbalance

There’s a slight imbalance in our therapeutics for bipolar disorder. While patients spend most of their time in the depressed phase, the FDA-approved treatments for mania outnumber those for depression 4 to 1.

First, here are my biases. In addition to the FDA-approved options, I will consider any treatment with at least one randomized, controlled trial that supports its merits. I tend to favor those with large effect sizes (eg, pramipexole) or low risks (eg, omega-3 fatty acids). I also value treatments with long-term data, even when their short-term benefits are debatable (eg, lamotrigine, psychotherapy). This is, after all, a chronic condition.

Mood-lifting stabilizers

The ideal treatment for bipolar depression would lift mood in the short term and prevent new episodes in the years to come. Examples of these mood-lifting stabilizers include lamotrigine, lithium, a few atypical antipsychotics (olanzapine-fluoxetine combination, quetiapine, lurasidone, cariprazine), and possibly valproate.1,2

Bipolar disorder may be chronic, but its episodes need not be.

How to choose among them? Collaborate. Adherence hovers around 50% in bipolar disorder, so it behooves us to ask patients about their hopes and fears in treatment. If fast results are desired, the atypical antipsychotics may be best. More often, patients value tolerability, in which case lamotrigine and lithium might come first. Practitioners often question lamotrigine’s efficacy and lithium’s tolerability, but new research suggests those reputations may be undeserved.3,4

Non-antidepressants for bipolar disorder

Next in line are medicines that can treat acute bipolar depression without destabilizing mood. These are best paired with a mood stabilizer, since they won’t prevent new episodes on their own. I have left antidepressants off this list because their mood-destabilizing potential has not escaped the eye of controlled studies.5 To be fair, all the options on this list probably have some mood-destabilizing potential, as this problem is notoriously difficult to detect in research (and in practice). The non-antidepressants that made the cut are pramipexole, modafinil, armodafinil, thyroid augmentation, omega-3 fatty acids (with more than 60% eicosapentaenoic acid), N-acetylcysteine, L-methylfolate, pioglitazone, and celecoxib.1,6-8

Pages

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.